Clinique Clémentville

Recent papers from Clinique Clémentville

1. Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control armJournal of Hematology & Oncology · 2026
2. Neoadjuvant atirmociclib plus letrozole versus letrozole alone in HR+/HER2− breast cancer: Results from FourLight-2, a randomized phase 2 window of opportunity study.Journal of Clinical Oncology · 2026
3. Prolonged survival with glofitamab in non-diffuse large B-cell lymphoma after CAR T-cell therapy relapseHaematologica · 2026
4. Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trialEuropean Journal of Cancer · 2026
5. Combined Lateral Patellofemoral Ligament and Lateral Patellotibial Ligament Reconstruction for Medial Patellar InstabilityArthroscopy Techniques · 2026
6. Germline BRCA1/2 Mutations in a Large Clinic-Based Cohort of Patients with Metastatic Breast Cancer in FranceCancers · 2026
7. Abstract PS3-10-28: Randomized phase II trial evaluating three anti-diarrheal prophylaxis strategies in patients (pts) with HER2+/HR+ early breast cancer (EBC) treated with extended adjuvant neratinib (dianer geicam/2018-06)Clinical Cancer Research · 2026
8. Abstract PS1-10-27: Progression-free survival (PFS) and overall survival (OS) results from the phase 3 MONALEESA-3 trial of postmenopausal patients with hormone receptor-positive (HR+)/HER2-negative (HER2−) advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL): A subgroup analysis of patients with invasive lobular carcinoma (ILC)Clinical Cancer Research · 2026
9. Rituximab for severe immune checkpoint inhibitor-related adverse events: a multicenter case seriesCancer Immunology Immunotherapy · 2026
10. Circulating tumor DNA dynamics and clinical outcomes in patients with advanced Colorectal Cancer treated with cetuximab-based induction and maintenance treatmentClinical Cancer Research · 2026
11. The BEVATOMOX phase II trial: raltitrexed/oxaliplatin/bevacizumab vs mFOLFOX6/bevacizumab in 2nd-line metastatic colorectal cancer.2026
12. Health-related quality of life after second-line axi-cel in transplant-ineligible patients with large B-cell lymphomaBlood Advances · 2026
13. Evaluation of physical rehabilitation in patients receiving curative treatment for head and neck cancer: The NUTRIMOUV randomized phase II trialSupportive Care in Cancer · 2025
14. Large B-cell lymphoma: The LYSA pragmatic guidelinesEuropean Journal of Cancer · 2025
15. Durvalumab after radiotherapy in patients with unresectable stage III non-small-cell lung cancer ineligible for chemotherapy: the DUART phase II nonrandomized controlled studyESMO Open · 2025
16. Assessment of Hemostatic Powder in Order to Prevent Staple Line Bleeding After Sleeve Gastrectomy in High-Risk Patients: A Multicentric Randomized Controlled TrialSurgical Technology Online · 2025
17. Using Virtual Reality During Chemotherapy to Support Emotional Regulation in Patients: Adding an Olfactory Reinforcement or Not?Virtual Worlds · 2025
18. The Role of Engagement in Virtual Reality to Enhance Emotional Well-Being in Breast Cancer Patients: A Mediation AnalysisCancers · 2025
19. Elacestrant in ESR1-mutant, endocrine-responsive metastatic breast cancer: should health authorities consider post hoc data to inform priority access?ESMO Open · 2024
20. 0548 A 5-year Multi-center Real-world Study Evaluating the Effectiveness and Use of CAD/CAM 3D-printed OAT to Treat OSASLEEP · 2024